...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacological research: The official journal of The Italian Pharmacological Society >Retrospective analysis of adverse drug reactions induced by gemcitabine treatment in patients with non-small cell lung cancer.
【24h】

Retrospective analysis of adverse drug reactions induced by gemcitabine treatment in patients with non-small cell lung cancer.

机译：吉西他滨治疗非小细胞肺癌患者药物不良反应的回顾性分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the world. Traditional chemotherapy for advanced NSCLC is often considered excessively toxic. Recent clinical trials documented that gemcitabine may represent a good therapeutical option in patients with NSCLC. Aim of our research was to retrospectively evaluate the adverse effects induced by gemcitabine in patients with NSCLC from 1 January 1997 to 31 December 2002, in clinical records of Oncology Divisions of "S. Giovanni di Dio" Hospital of Crotone, "Ospedali Riuniti" Hospital of Reggio Calabria, Hospital of Paola, and in Pneumological Oncology Division of "Mariano Santo" Hospital of Cosenza, Italy. Clinical records of patients treated with gemcitabine (1000mgm(-2) on days 1 and 8) were reviewed and following data were obtained: sex and age of the patients, histologic diagnosis and disease stage, World Health Organisation (WHO) performance status and toxic effects induced by gemcitabine. We reported that 71.6% of NSCLC patients (age range 48-77 years; 135 males, 27 females; performance status 0=53, 1=109) were eligible for our study. Side effect of gemcitabine involved gastrointestinal system (nausea, vomiting and diarrhoea) and only in the last cycles (VIII-XI) emopoiethic system (leukopenia, neutropenia, thrombocytopenia and anemia). Grade IV vomiting occurred in three patients, thrombocytopenia in two. Grade III leukopenia was observed in three patients. Other toxicities were mild. None of the patients died during chemotherapy.In conclusion, these data showed that gemcitabine present a very good tolerability in patients with NSCLC. Therefore, it could be considered as a new therapeutic agents to use as first line therapy for this disease.
机译：非小细胞肺癌（NSCLC）是世界上导致癌症死亡的主要原因。晚期非小细胞肺癌的传统化学疗法通常被认为毒性太大。最近的临床试验表明，吉西他滨可能代表NSCLC患者的良好治疗选择。我们的研究目的是回顾性评估1997年1月1日至2002年12月31日吉西他滨对非小细胞肺癌患者的不良反应，在克罗托内的“ S. Giovanni di Dio”医院，“ Ospedali Riuniti”医院的肿瘤科临床记录中意大利Paola医院Reggio Calabria医院和意大利科森扎“ Mariano Santo”医院肺肿瘤科。回顾了吉西他滨（第1天和第8天）治疗的患者的临床记录（1000mgm（-2）），并获得了以下数据：患者的性别和年龄，组织学诊断和疾病分期，世界卫生组织（WHO）的表现状态和毒性吉西他滨引起的效应。我们报道有71.6％的NSCLC患者（年龄在48-77岁之间;男性135例，女性27例;表现状态0 = 53，1 = 109）符合我们的研究条件。吉西他滨的副作用涉及胃肠道系统（恶心，呕吐和腹泻），仅在最后一个周期（VIII-XI）的上皮系统（白细胞减少症，中性粒细胞减少症，血小板减少症和贫血）中起作用。 IV级呕吐发生在3例患者中，血小板减少症发生在2例中。在三名患者中观察到III级白细胞减少症。其他毒性轻微。总之，所有患者均未在化疗期间死亡。这些数据表明，吉西他滨对NSCLC患者具有很好的耐受性。因此，可以认为它是作为该疾病的一线疗法的新治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号